Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine
- Conditions
- Allergic Rhinitis
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 220
- Registration Number
- NCT00636870
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Continuous Glucose Monitoring System (CGMS) in Type 2 Diabetic Patients Inadequately Controlled by Metformine Monotherapy; Analyze of Glycemic Profile Before and After Association of Glimepiride
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2008-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 43
- Registration Number
- NCT00633425
- Locations
- 🇫🇷
Sanofi-Aventis, Paris, France
A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis
- Conditions
- Osteoporosis, Postmenopausal
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2008-03-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 464
- Registration Number
- NCT00632216
Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma
- Conditions
- HyperuricemiaLeukemiaLymphoma
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2009-10-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 50
- Registration Number
- NCT00631579
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 825
- Registration Number
- NCT00629551
- Locations
- 🇿🇦
Sanofi-Aventis Administrative Office, Midrand, South Africa
Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology
- Conditions
- Urinary Bladder Neurogenic
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2009-12-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 29
- Registration Number
- NCT00629720
- Locations
- 🇷🇸
Sanofi-Aventis Administrative Office, Belgrade, Serbia
Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia
- Conditions
- Sleep Initiation and Maintenance Disorders
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 113
- Registration Number
- NCT00630175
- Locations
- 🇨🇦
Sanofi-Aventis Administrative Office, Laval, Canada
Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)
- First Posted Date
- 2008-03-03
- Last Posted Date
- 2010-06-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 9
- Registration Number
- NCT00627471
- Locations
- 🇦🇷
Sanofi-aventis administrative office Argentina, Buenos Aires, Argentina
Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 337
- Registration Number
- NCT00625664
- Locations
- 🇺🇸
Sanofi-Aventis Investigational Site Number 840033, San Diego, California, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840036, Seattle, Washington, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840020, Bethlehem, Pennsylvania, United States
Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2010-12-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 8329
- Registration Number
- NCT00622648
- Locations
- 🇹🇳
Sanofi-Aventis Administrative Office, Megrine, Tunisia